PharmaLogic Atlanta site expands PET radiopharma capacity
PharmaLogic opened a PET radiopharmaceutical manufacturing facility in Atlanta to expand production and distribution across the Southeast. The site is part of a $250M U.S. infrastructure investment.
PharmaLogic Holdings has opened a PET radiopharmaceutical manufacturing facility in Atlanta, expanding its U.S. production network for diagnostic and therapeutic radiopharmaceuticals.
The company said the facility will increase production capacity and support research and development of novel radiopharmaceuticals. Its Atlanta location is intended to improve delivery of time-sensitive PET agents to hospitals and imaging centers across the Southeast.
PharmaLogic is a contract development and manufacturing organization focused on radiopharmaceuticals. The company described the Atlanta site as part of a broader effort to strengthen domestic radiopharmaceutical manufacturing infrastructure and improve patient access to advanced nuclear medicine agents.
The opening is part of a $250M investment in U.S. radiopharmaceutical infrastructure. PharmaLogic said the Atlanta facility follows recent openings in Cincinnati; the Bronx, NY; Salt Lake City; and Los Angeles.
“The opening of our Atlanta facility marks another critical step in our $250 million investment to address the deficit of radiopharmaceutical infrastructure in the U.S.,” said Etienne Montagut, president and CEO of PharmaLogic.
The company said the site will support access to advanced radiopharmaceuticals in the Southeast and surrounding areas. It also described the facility as a hub for development of next-generation radiopharmaceuticals.
PET radiopharmaceutical manufacturing is highly location-sensitive because many agents have short physical half-lives and require fast delivery after production. Regional manufacturing sites can therefore affect whether hospitals and imaging centers can reliably schedule PET studies and support emerging clinical programs.
The new Atlanta site is also relevant to theranostics and drug-development workflows. As more diagnostic and therapeutic radiopharmaceuticals move through clinical development and commercialization, production capacity, quality systems, and regional distribution networks are becoming more important to nuclear medicine operations.
PharmaLogic’s network currently delivers more than 2.5M doses annually, according to the company. The firm said the Atlanta expansion adds capacity for both commercial production and research activities.
The Atlanta opening does not announce a specific new tracer approval or clinical trial. The main development is infrastructure: additional PET manufacturing capacity in a region where fast distribution can determine practical access to radiopharmaceutical imaging.
Company:PharmaLogic
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Niowave breaks ground on $75M Ac-225 production facility
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
GE HealthCare, UW Medicine launch imaging research collaboration
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm launches balloon-less EBUS bronchoscope
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST wins FDA clearance for Pro Diagnostic System
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M raise for breast imaging platform
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.